1 April 2018 - The April 2018 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The April issue of the Schedule includes a number of new/revised listings:

• Aflibercept (Eylea) - restriction change
  
• Atezolizumab (Tecentriq) - new medicine
  
• Budesonide with eformoterol fumarate dehydrate (DuoResp Spiromax) - new formulation
  
• Certolizumab (Cimzia) - new formulation
  
• Dapagliflozin propanediol monohydrate (Forxiga) - new indication
  
• Dapagliflozin propanediol monohydrate with metformin hydrochloride (XigDuo XR) - new indication
  
• Dexamethasone (Ozurdex) - restriction change
  
• Dexamethasone (Ozurdex) - new indication
  
• Empagliflozin (Jardiance) - new indication
  
• Linagliptin with empagliflozin (Glyxambi) - new indication
  
• Glycomacropeptide and essential amino acids with vitamins and minerals (Tylactin Complete) - new formulation
  
• Glycomacropeptide and essential amino acids with vitamins and minerals (PKU Build 10, PKU Build 20) - new formulation
  
• Insulin glargine (Toujeo Solostar) - new strength
  
• Linagliptin (Trajenta) - new indication
  
• Linagliptin with metformin hydrochloride (Trajentamet) - new indication
  
• Methotrexate sodium (Trexject) - new formulation
  
• Pralatrexate (Folotyn) - new medicine
  
• Ranibizumab (Lucentis)  - restriction change
  
• Saxagliptin hydrochloride with dapagliflozin propanediol monohydrate (Qtern) - new combination product
  
• Sonidegib phosphate (Odomzo) - new medicine
  
• Tenofovir disoproxil fumarate with emtricitabine (Truvada, etc.) - new indication
  
• Verteporfin (Visudyne) - restriction change
  

Read summary of PBS changes